Why the study?
Does doxorubicin treatment alter protein expression profiles in H9c2 cardiomyocytes?
Does doxorubicin treatment alter protein expression profiles in H9c2 cardiomyocytes?
Proteomic profiling of doxorubicin-treated cardiomyocytes identified 22 differentially expressed proteins, highlighting cathepsin B and NF-κB as potential mediators of doxorubicin-induced cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Doxorubicin alters cardiomyocyte protein expression; hypothesis-generating for cathepsin B and NF-κB roles pending in vivo validation.
The study was performed to analyze the proteomic profiling of doxorubicin-treated H9c2 cardiomyocytes in order to identify novel protein biomarkers associated with doxorubicin-induced cardiomyopathy. The protein profiling of H9c2 cells in response to doxorubicin at an apoptosis-induced concentration of 0.5 μM were compared using iTRAQ analysis. Western-blot analysis was used to confirm differentially expressed proteins identified in the proteomic study. A total of 22 differently expressed proteins were identified in doxorubicin-treated H9c2 cells including 15 up-regulated and 7 down-regulated proteins. Gene Ontology (GO) analysis revealed that 10 altered proteins were enriched in the process of apoptosis. We further validated the expression of cathepsin B and its possible regulator nuclear factor kappa B (NF-κB) in H9c2 cells were increased during doxorubicin treatment using Western-blots. Differentially expressed proteins might provide clues to clarify novel mechanisms underlying doxorubicin-induced cardiomyopathy. Our results also suggest that increased cathepsin B expression might be associated with NF-κB up-regulation, and the exact mechanisms need to be clarified.
No takes yet. Share an insight, caveat, or question.
A 2012 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: